ReGenTree has initiated a phase 3 clinical trial, called ARISE-3, to evaluate the safety and efficacy of 0.1% RGN-259 eye drops for the treatment of dry eye syndrome. The company is a US-based joint venture company between GtreeBNT and RegeneRx Biopharmaceuticals. ARISE-3 is a randomized, double-masked, placebo-controlled trial which will evaluate the 0.1% RGN-259 eye […]
Sun Pharmaceutical Industries Ltd. has received approval from the U.S. Food and Drug Administration (FDA) for CEQUA (cyclosporine ophthalmic solution) 0.09%, a significant advancement in the treatment of keratoconjunctivitis sicca, commonly known as dry eye disease. This approval introduces a new therapeutic option for a condition that affects millions worldwide, addressing a substantial unmet medical […]
